Philippe Wiesel has been our Chief Medical Officer since January 2021. Previously, from August 2010 to December 2020, Dr. Wiesel was the Chief Medical Officer at Genkyotex SA, a clinical development company developing treatment for fibrotic disorders in the liver, lung, and kidney, which was acquired by Calliditas Therapeutics AB in 2021. Prior to this role, Dr. Wiesel co-founded Genexion SA, which was focused on developing early-stage clinical assets in partnership with emerging biotechnology companies. Before this, Dr. Wiesel was Medical Director at EMD Serono, Inc., where he was involved with the global development of several biologics. In particular, he led the late-stage clinical development of Raptiva, achieving the first marketing authorization in Europe for a biological therapy targeting psoriasis. Dr. Wiesel received an M.D. in Medicine from Lausanne University Medical School and was a postdoctoral researcher at Harvard University Medical School and the Division of Hypertension at Lausanne University.